The price of the follow-on drugs of the anti-depressant ‘desvenlafaxine’ that had been listed at 90% of the price of its original by avoiding the original’s patent through salt alterations have fallen greatly after a year and a half due to the adjustment of the price cap that was conducted following an investigation into their actual transaction price.

In other words, the companies’ efforts to develop formulations to receive a higher drug price were all in vain.

Four companies including Hanlim Pharm, Myung-In Pharm, Nexpharm, and Whan In Pharm had first received approvals for their incrementally modified desvenlafaxine drugs on April 7th, 2020.

The four drugs were a